{
    "clinical_study": {
        "@rank": "87171", 
        "arm_group": [
            {
                "arm_group_label": "Placebo comparator", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "E2006", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single-center, randomized, double-blind, placebo-controlled, sequential,\n      multiple-dose study. The study will be conducted in two parts:  Part A (6 cohorts of healthy\n      adults receiving evening dosing) and Part B (one cohort of elderly adults receiving evening\n      dosing)."
        }, 
        "brief_title": "2-Part Multiple Ascending Dose Study for Safety and Pharmacokinetics in Healthy and Elderly Subjects", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "CNS", 
        "eligibility": {
            "criteria": {
                "textblock": "Included:\n\n          -  Healthy males or females, ages 18 to 55 years (Part A) or 65 to 80 years (Part B)\n\n          -  Who report typical time in bed 7.5 to 9  hours\n\n          -  Who report typical bedtime 22:00 - 24:00 and typical wake time 06:00 - 08:00\n\n          -  Who report typical sleep latency of <= 30 minutes\n\n          -  All females must be of non-childbearing potential, or subjects who have been\n             sterilized surgically or who are otherwise proven sterile. Females must have a\n             negative serum beta-human chorionic gonadotropin (Beta-hCG) test result at Screening\n             and a negative urine pregnancy test at Baseline.\n\n          -  Body mass index BMI > 18 and  32 kg/m2 at Screening\n\n        Excluded:\n\n          -  Performed shift work within 2 weeks prior to Screening\n\n          -  Had taken a flight across three or more time zones in the 7 days prior to Screening\n\n          -  Female subjects who are nursing\n\n          -  With a history of gastrointestinal surgery (hepatectomy, nephrectomy, digestive organ\n             resection, etc.) that may affect PK profile of E2006\n\n          -  With a known history of clinically significant drug or food allergies or presently\n             experiencing significant seasonal allergy\n\n          -  Hypersensitivity to the study drug or any of the excipients"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01673451", 
            "org_study_id": "E2006-A001-002"
        }, 
        "intervention": [
            {
                "arm_group_label": "E2006", 
                "description": "Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules", 
                "intervention_name": "E2006", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo comparator", 
                "description": "E2006-matched placebo (Part A and Part B); Part B:  dose level to be determined based on results of Part A, administered as capsules", 
                "intervention_name": "Placebo comparator", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "insomnia", 
        "lastchanged_date": "October 10, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Culver City", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90232"
                    }, 
                    "name": "Parexel, California Clinical Trials"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Glendale", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91206"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of E2006 in Healthy Adult and Elderly Subjects", 
        "overall_official": {
            "affiliation": "Parexel", 
            "last_name": "Dohwa Kim", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Incidence of Adverse events (AEs)", 
            "safety_issue": "Yes", 
            "time_frame": "28 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01673451"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Plasma concentrations of E2006", 
            "safety_issue": "No", 
            "time_frame": "Part A up to 288 hours postdose; Part B: up to 324 hours postdose"
        }, 
        "source": "Eisai Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eisai Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}